Thanh bên bài viết

PDF
Ngày xuất bản: 18/04/2023
Số lượt xem tóm tắt: 138
Số lượt xem PDF: 111
DOI: https://doi.org/10.51298/vmj.v525i1.5045
Số xuất bản
Tập 525 Số 1 (2023): Vietnam Medical Association
Chuyên mục
Các bài báo
Trích dẫn bài báo
Thi Kim Oanh, N. ., Thanh Tung, N. ., Quang Dong, N. ., & Thanh Viet, N. (2023). ANTIMICROBIAL SUSCEPTIBILITY PATTERNS OF ESCHERICHIA COLI ISOLATED FROM CANCER PATIENTS IN NATIONAL CANCER HOSPITAL. Tạp Chí Y học Việt Nam, 525(1). https://doi.org/10.51298/vmj.v525i1.5045

ANTIMICROBIAL SUSCEPTIBILITY PATTERNS OF ESCHERICHIA COLI ISOLATED FROM CANCER PATIENTS IN NATIONAL CANCER HOSPITAL

Thi Kim Oanh Ninh 1, Thanh Tung Nguyen 2, Quang Dong Nguyen 3, Thanh Viet Nguyen3,
1 Hanoi Medical University
2 National Cancer Hospital
3 National Hospital of Burns

Nội dung chính của bài viết

Tóm tắt

Introduction: Escherichia coli (E. coli) is one of the leading causes of infections in cancer patients. Antibiotic-resistant E. coli is a major cause of treatment failure in infected cancer patients. This study aims to determine the prevalence and antibiotic susceptibility of E. coli in cancer patients from January 2022 to December 2022 at National Cancer Hospital. Materials and methods: We performed a retrospective review of the culture results of various clinical samples. Results: A total of 283 samples were analyzed to identify E. coli and its antimicrobial profiles. The prevalence of E. coli was 15.9%. The highest isolation rate was obtained from blood samples (35.56%). The highest rate of E. coli resistance was found in ampicillin (95.56%), followed by sulfamethoxazole/trimethoprim (77.76%) and ceftazidime (64.44%). The highest rate of E. coli sensitivity was found in fosfomycin (97.78%), followed by ertapenem, imipenem, meropenem, and amikacin (95.56% each), and nitrofurantoin (93.33%). About 55.56% and 80.0% were ESBL-positive and multidrug-resistant, respectively. Conclusion: E. coli isolates showed high rates of resistance to ampicillin, sulfamethoxazole/ trimethoprim, and ceftazidime. Fosfomycin, ertapenem, imipenem, meropenem, amikacin, and nitrofurantoin are considered appropriate for the empirical treatment of E. coli. Regular monitoring of E. coli resistant to antibiotics is recommended.

Chi tiết bài viết

Từ khóa

E. coli, antibiotics, Burns, cancer, Vietnam

Tài liệu tham khảo

1. De Francesco MA, Ravizzola G, Peroni L, Negrini R, Manca N. Urinary tract infections in Brescia, Italy: etiology of uropathogens and antimicrobial resistance of common uropathogens. Medical science monitor : international medical journal of experimental and clinical research. 2007;13(6):136-44.
2. Wu D, Ding Y, Yao K, Gao W, Wang Y. Antimicrobial Resistance Analysis of Clinical Escherichia coli Isolates in Neonatal Ward. Frontiers in pediatrics. 2021;9:670470.
3. Fentie A, Wondimeneh Y, Balcha A, Amsalu A, Adankie BT. Bacterial profile, antibiotic resistance pattern and associated factors among cancer patients at University of Gondar Hospital, Northwest Ethiopia. Infection and drug resistance. 2018;11:2169-78.
4. Sherchan JB, Hayakawa K, Miyoshi-Akiyama T, Ohmagari N, Kirikae T, Nagamatsu M, et al. Clinical epidemiology and molecular analysis of extended-spectrum-beta-lactamase-producing Escherichia coli in Nepal: characteristics of sequence types 131 and 648. Antimicrobial agents and chemotherapy. 2015;59(6):3424-32.
5. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrobial agents and chemotherapy. 2013;57(10):4605-7.
6. Bhat S, Muthunatarajan S, Mulki SS, Archana Bhat K, Kotian KH. Bacterial Infection among Cancer Patients: Analysis of Isolates and Antibiotic Sensitivity Pattern. International journal of microbiology. 2021;2021:8883700.
7. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Current opinion in infectious diseases. 2011;24(6):545-53.
8. Tanwar J, Das S, Fatima Z, Hameed S. Multidrug resistance: an emerging crisis. Interdisciplinary perspectives on infectious diseases. 2014;2014:541340.